ãã€ãªãã¯ãããžãŒäŒæ¥ã§ããã¢ãã¯ãµã»ãã€ãªãµã€ãšã³ã¹ç€Ÿã¯ãè
«çåŠãšææçã«ãããéå€§ãªæªå
è¶³ããŒãºã«çŠç¹ãåœãŠãæ²»çæ³ãšã¯ã¯ãã³ãéçºããŠããŸããåç€Ÿã®æ²»çããã°ã©ã ã«ã¯ãåµå·£ããã®æ²»çã«çŠç¹ãåœãŠããã¡ã©å
åæ³å容äœT现èæè¡ããã¡ã©æåå容äœT现èïŒCAR-TïŒæè¡ã®æ°ãã圢ã®éçºãããã³ãŠã€ã«ã¹ã®ç¹å®ã®ãŠã€ã«ã¹ã¿ã³ãã¯è³ªæ©èœã®é»å®³ã«çŠç¹ãåœãŠãCOVID-19æ²»ççšã®æãŠã€ã«ã¹è¬åè£ã®çºèŠãšéçºãå«ãŸããŸããã¯ã¯ãã³ããã°ã©ã ã«ã¯ãããªãã«ãã¬ãã£ãä¹³ããã«å¯Ÿããã¯ã¯ãã³ã®éçºãšåµå·£ããã«å¯Ÿããã¯ã¯ãã³ãå«ãŸããŸããå瀟ã¯ãŸããããã«å¯Ÿããå
ç«çæ³è¬ã®éçºãè¡ã£ãŠããŸããå瀟ã¯MolGenie GmbHãšååå¥çŽãçµã³ãCOVID-19ã«å¯ŸããæãŠã€ã«ã¹è¬åè£ãçºèŠããã³éçºããŠããŸããå瀟ã¯ä»¥å㯠ITUS Corporation ãšããŠç¥ãããŠããŸãããã2018 幎 10 æã« Anixa Biosciences, Inc. ã«ç€Ÿåã倿ŽããŸãããAnixa Biosciences, Inc. 㯠1982 幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ãµã³ããŒã«æ¬ç€Ÿã眮ããŠããŸãã